Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia; ODM derived from:


Versions (1) ▾
  1. 3/7/17
Uploaded on:

March 7, 2017

No DOI assigned. To request one pleaselog in.
Creative Commons BY-NC 3.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Leukemia, Myeloid NCT00611247

Eligibility Leukemia, Myeloid NCT00611247

Inclusion Criteria
Exclusion Criteria